AU2014234105B2 - Sodium channel modulators for the treatment of pain - Google Patents

Sodium channel modulators for the treatment of pain Download PDF

Info

Publication number
AU2014234105B2
AU2014234105B2 AU2014234105A AU2014234105A AU2014234105B2 AU 2014234105 B2 AU2014234105 B2 AU 2014234105B2 AU 2014234105 A AU2014234105 A AU 2014234105A AU 2014234105 A AU2014234105 A AU 2014234105A AU 2014234105 B2 AU2014234105 B2 AU 2014234105B2
Authority
AU
Australia
Prior art keywords
chloro
compound
pain
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014234105A
Other languages
English (en)
Other versions
AU2014234105A1 (en
Inventor
Olga BABICH
Robert Z. Luo
David J. Palling
Srinivasan P. Venkatachalan
Yanlin WANG-FISCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of AU2014234105A1 publication Critical patent/AU2014234105A1/en
Application granted granted Critical
Publication of AU2014234105B2 publication Critical patent/AU2014234105B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014234105A 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain Ceased AU2014234105B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787618P 2013-03-15 2013-03-15
US61/787,618 2013-03-15
PCT/US2014/025809 WO2014151472A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Publications (2)

Publication Number Publication Date
AU2014234105A1 AU2014234105A1 (en) 2015-09-03
AU2014234105B2 true AU2014234105B2 (en) 2019-01-03

Family

ID=51580969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014234105A Ceased AU2014234105B2 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Country Status (16)

Country Link
US (1) US10179781B2 (https=)
EP (1) EP2968234B1 (https=)
JP (1) JP6449845B2 (https=)
KR (1) KR20150131254A (https=)
CN (1) CN105188694B (https=)
AU (1) AU2014234105B2 (https=)
BR (1) BR112015022096A8 (https=)
CA (1) CA2900604A1 (https=)
ES (1) ES2687481T3 (https=)
HK (1) HK1219060A1 (https=)
IL (1) IL242564A0 (https=)
MX (1) MX363680B (https=)
MY (1) MY188139A (https=)
PH (1) PH12015501740A1 (https=)
RU (1) RU2669367C2 (https=)
WO (1) WO2014151472A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
CA2900604A1 (en) 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
UA120353C2 (uk) * 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3359151A4 (en) 2015-10-07 2019-08-14 Arizona Board of Regents on behalf of the University of Arizona CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
AU2016370554B2 (en) 2015-12-18 2018-11-29 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN112689636B (zh) 2018-09-10 2024-08-20 科研制药株式会社 新型杂原子芳香族酰胺衍生物以及含有其的药剂
WO2020161606A1 (en) * 2019-02-04 2020-08-13 Simon Fraser University Methods and compounds for inhibition of inactivation of voltage-gated sodium channels
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
US12533341B2 (en) 2019-12-11 2026-01-27 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079443A1 (en) * 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
WO2012004714A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
WO2012004743A1 (en) * 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
WO2012004706A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
EP1368355B1 (de) * 2001-03-14 2006-06-07 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
RU2006107211A (ru) * 2003-08-08 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
AU2005266090A1 (en) * 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
CA2693588C (en) * 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
EP2435407B1 (en) 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
ES2532357T3 (es) * 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
CA2823707A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
CA2900604A1 (en) 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
WO2015035223A1 (en) 2013-09-09 2015-03-12 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
UA120353C2 (uk) * 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079443A1 (en) * 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
WO2012004714A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
WO2012004743A1 (en) * 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
WO2012004706A2 (en) * 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds

Also Published As

Publication number Publication date
HK1219060A1 (zh) 2017-03-24
EP2968234A4 (en) 2016-10-12
PH12015501740A1 (en) 2015-10-19
RU2015133310A (ru) 2017-04-20
MX363680B (es) 2019-03-29
WO2014151472A1 (en) 2014-09-25
JP6449845B2 (ja) 2019-01-09
CN105188694B (zh) 2018-07-31
EP2968234A1 (en) 2016-01-20
AU2014234105A1 (en) 2015-09-03
MX2015011907A (es) 2016-05-16
JP2016512844A (ja) 2016-05-09
IL242564A0 (en) 2016-02-29
MY188139A (en) 2021-11-23
CA2900604A1 (en) 2014-09-25
US10179781B2 (en) 2019-01-15
BR112015022096A8 (pt) 2019-11-26
US20160046617A1 (en) 2016-02-18
KR20150131254A (ko) 2015-11-24
EP2968234B1 (en) 2018-06-27
ES2687481T3 (es) 2018-10-25
RU2669367C2 (ru) 2018-10-11
RU2015133310A3 (https=) 2018-02-28
CN105188694A (zh) 2015-12-23
BR112015022096A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
AU2014234105B2 (en) Sodium channel modulators for the treatment of pain
AU2014318979B2 (en) Sodium channel modulators for the treatment of pain and diabetes
CN107001283B (zh) Flt3受体拮抗剂
CN112513020B (zh) 用于治疗疾病的kdm1a抑制剂
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
RS57331B1 (sr) Inhibitori demetilaze za lsd1 zasnovani na arilciklopropilaminu i njihova medicinska upotreba
WO2011007819A1 (ja) ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
CN102971307A (zh) 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
MX2015002310A (es) Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
JP2024539268A (ja) Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順
CN108602807B (zh) 杂环磺酰胺衍生物及含有其的药物
WO2016040315A1 (en) Selective nav1.7 inhibitors for the treatment of diabetes
CN111253403B (zh) 氨基吡喃氘代衍生物及其组合物和应用
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes
CN101668755A (zh) 治疗疼痛的治疗剂

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 03 MAY 2019

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired